CinCor Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CINC research report →
Companywww.cincor.com
CinCor Pharma, Inc. , a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.
- CEO
- Marc M. P. de Garidel
- IPO
- 2022
- Employees
- 19
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $1.27B
- P/E
- -20.44
- P/S
- 0.00
- P/B
- -16.15
- EV/EBITDA
- -32.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 110.68%
- ROIC
- -34.11%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-50,347,433 · -126.16%
- EPS
- $-1.42 · -49.47%
- Op Income
- $-42,510,406
- FCF YoY
- -77.32%
Performance & Tape
- 52W High
- $43.15
- 52W Low
- $10.53
- 50D MA
- $25.59
- 200D MA
- $25.14
- Beta
- 0.00
- Avg Volume
- 625.75K
Get TickerSpark's AI analysis on CINC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 23 | 5AM Partners VI, LLC | other | 496,323 |
| Feb 24, 23 | HEALY JAMES | other | 9,803 |
| Feb 24, 23 | HEALY JAMES | sell | 19,608 |
| Nov 28, 22 | HEALY JAMES | sell | 6,000 |
| Feb 24, 23 | HEALY JAMES | other | 6,073,949 |
| Feb 24, 23 | Freeman Mason | other | 2,494 |
| Jun 10, 22 | Freeman Mason | sell | 6 |
| Feb 24, 23 | Freeman Mason | other | 100 |
| Feb 24, 23 | Freeman Mason | sell | 40,000 |
| Feb 24, 23 | Freeman Mason | sell | 30,178 |
Our CINC Coverage
We haven't published any research on CINC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CINC Report →